Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Absci Corporation - Common Stock
(NQ:
ABSI
)
10.78
-1.32 (-10.95%)
Delayed Quote
Updated: 3:26 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Absci Corporation - Common Stock
< Previous
1
2
3
4
5
Next >
Absci to Participate in Upcoming Investor Conferences
October 27, 2026
From
Absci Corporation
Via
GlobeNewswire
AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.
October 21, 2026
News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.
From
Wall Street Investor
Via
GlobeNewswire
AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
October 14, 2026
From
Biotech Insider
Via
GlobeNewswire
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
October 13, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
September 24, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
September 01, 2026
From
Absci Corporation
Via
GlobeNewswire
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
August 19, 2026
News Provided by USA News Group on behalf of MindWalk Holdings Corp.
From
USA News Group
Via
GlobeNewswire
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
August 11, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
July 14, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
June 24, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
June 24, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
May 20, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
May 07, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
April 23, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
March 24, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic
March 24, 2026
Experts at the forefront of reproductive medicine, fertility, and translational research will guide the clinical research program for a new therapeutic antibody treatment
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
March 03, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026
February 24, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
February 17, 2026
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 16, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization
December 11, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research
December 10, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
December 04, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results
November 12, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
October 29, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
October 27, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
October 15, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
September 11, 2025
Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs
From
Absci Corporation; Oracle; AMD
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
